Compare Globus Medical Inc. Class A Common Stock (GMED) vs iShares iBoxx $ High Yield Corporate Bond ETF (HYG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs iShares iBoxx $ High Yield Corporate Bond ETF — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while iShares iBoxx $ High Yield Corporate Bond ETF trades at $76.76 (market cap $17.66B). The key difference: iShares iBoxx $ High Yield Corporate Bond ETF is the larger of the two by market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, iShares iBoxx $ High Yield Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and iShares iBoxx $ High Yield Corporate Bond ETF for 61 Days on average.
| GMED | HYG | |
|---|---|---|
Market Cap | $10.25B | $17.66B |
Volume | 1,108,124 | 60,522,261 |
Sector | Health | Fixed Income |
52-Week High | $96.82 | $81.28 |
52-Week Low | $58.33 | $76.81 |
Typical Hold Time | 0 Days | 61 Days |
Enterprise Value | $9.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
HYG trades at $77.09, down 0.26% amid a bearish technical signal with moving averages indicating selling pressure. The ETF shows neutral oscillator readings with mixed RSI signals. Recent corporate actions include dividend payments scheduled for 2026. The broader bond market faces pressure from rising Treasury yields, with the 10-year yield hitting levels not seen since 2007 according to MarketBeat on September 30, 2026.
The outlook remains cautious as high yield corporate bonds face headwinds from rising interest rates and inflationary pressures. Investment opportunities exist for income-focused investors through scheduled dividends, but risks include continued bond market volatility and economic uncertainty. HYG's performance will be closely tied to Federal Reserve policy and corporate credit conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About iShares iBoxx $ High Yield Corporate Bond ETF
HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.
Read more on HYG →
